Roche executive says ultra-rare diseases outside core

By Ben Hirschler LONDON (Reuters) – Treating ultra-rare diseases is a distinct business from Roche's current area of expertise, the Swiss group's head of pharmaceuticals said, in comments that may cast doubt on its interest in Alexion Pharmaceuticals. "Our business is based on personalized healthcare and defining the patients most at risk and finding therapies," Daniel O'Day said in an interview during a visit to London this week. …